Keros Therapeutics Files 8-K

Ticker: KROS · Form: 8-K · Filed: Jun 9, 2025 · CIK: 1664710

Keros Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyKeros Therapeutics, Inc. (KROS)
Form Type8-K
Filed DateJun 9, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-event, filing

TL;DR

Keros Therapeutics filed an 8-K on 6/9/25 covering votes and other events.

AI Summary

Keros Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting on matters submitted to a vote of security holders and other events. The filing includes financial statements and exhibits related to the period ending June 4, 2025. The company is incorporated in Delaware and its principal executive offices are located in Lexington, Massachusetts.

Why It Matters

This 8-K filing provides an update on Keros Therapeutics' corporate activities, including any votes by security holders and other significant events, which can impact investor understanding of the company's governance and operations.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on corporate events and does not appear to contain significant new financial or operational disclosures that would immediately alter the company's risk profile.

Key Players & Entities

  • Keros Therapeutics, Inc. (company) — Registrant
  • June 4, 2025 (date) — Earliest event reported
  • June 9, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of incorporation
  • Lexington, Massachusetts (location) — Principal executive offices

FAQ

What specific matters were submitted to a vote of Keros Therapeutics' security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What are the key dates associated with this 8-K filing?

The earliest event reported is June 4, 2025, and the filing date is June 9, 2025.

Where are Keros Therapeutics' principal executive offices located?

Keros Therapeutics' principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts, 02421.

What is Keros Therapeutics' standard industrial classification?

Keros Therapeutics' standard industrial classification is Pharmaceutical Preparations [2834].

What is the SEC file number for Keros Therapeutics?

The SEC file number for Keros Therapeutics is 001-39264.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 9, 2025 regarding Keros Therapeutics, Inc. (KROS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.